CARDIOME REPORTS ADDITIONAL TRIAL DATA FOR RSD1235

Cardiome has reported additional results from a Phase I study for RSD1235 for the prevention of recurrence of atrial fibrillation.

The trial tested the tolerability and pharmacokinetics of RSD1235 with repeat oral dosing in healthy volunteers.

No clinically relevant changes were found in clinical laboratory, vital signs or ECG measurements, and there were no serious adverse events.